Literature DB >> 8920930

Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein.

S Chandler1, J Cossins, J Lury, G Wells.   

Abstract

The matrix metalloproteinases (MMPs) are a group of enzymes which have the ability to degrade extracellular matrix. They also cleave non-matrix proteins such as myelin basic protein and alpha 1-antitrypsin and they are able to process tumour necrosis factor-alpha (TNF) to its mature form. We have cloned, expressed and purified human macrophage metalloelastase (EC 3.4.24.65), an MMP recognised for its ability to degrade elastin, but whose substrate specificity has not yet been defined. With the exception of type I collagen this enzyme degraded all matrix proteins tested, namely: type IV collagen, type I gelatin, fibronectin, laminin, vitronectin and proteoglycan. It also degraded myelin basic protein, cleaved alpha 1-antitrypsin and released TNF from a pro-TNF fusion protein. Thus, in common with several other MMPs, macrophage metalloelastase has a broad substrate range which extends beyond that of elastin alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920930     DOI: 10.1006/bbrc.1996.1677

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  52 in total

1.  Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas.

Authors:  Koichi Shimizu; Masayoshi Shichiri; Peter Libby; Richard T Lee; Richard N Mitchell
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

2.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  In vivo testing of an injectable matrix gel for the treatment of shoulder cuff muscle fatty degeneration.

Authors:  Tai Huynh; John Taehwan Kim; Grady Dunlap; Shahryar Ahmadi; Jeffrey C Wolchok
Journal:  J Shoulder Elbow Surg       Date:  2020-06-09       Impact factor: 3.019

Review 4.  The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease.

Authors:  I A Scarisbrick
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

Review 5.  MMP-12, a Promising Therapeutic Target for Neurological Diseases.

Authors:  Bharath Chelluboina; Koteswara Rao Nalamolu; Jeffrey D Klopfenstein; David M Pinson; David Z Wang; Raghu Vemuganti; Krishna Kumar Veeravalli
Journal:  Mol Neurobiol       Date:  2017-02-02       Impact factor: 5.590

6.  Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope.

Authors:  Cheryl A D'Souza; Mario A Moscarello
Journal:  Neurochem Res       Date:  2006-07-27       Impact factor: 3.996

7.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

Authors:  M T Salmela; T T MacDonald; D Black; B Irvine; T Zhuma; U Saarialho-Kere; S L F Pender
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Neurotoxic effects of polymorphonuclear granulocytes on hippocampal primary cultures.

Authors:  Klaus Dinkel; Firdaus S Dhabhar; Robert M Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-18       Impact factor: 11.205

9.  Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment.

Authors:  Rajagopalan Bhaskaran; Mark O Palmier; Nusayba A Bagegni; Xiangyang Liang; Steven R Van Doren
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

10.  MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage.

Authors:  Hideo Kobayashi; Sharmila Chattopadhyay; Kinshi Kato; Jennifer Dolkas; Shin-Ichi Kikuchi; Robert R Myers; Veronica I Shubayev
Journal:  Mol Cell Neurosci       Date:  2008-09-05       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.